Moreover, CML patients carrying the GG genotype for NFE2L2 rs13001694 had a significantly lower overall survival time (HR = 11.86, 95%CI = 1.39–100.7, p = 0.023) compared with those that were allele A carriers (Figure 1c), with an average overall survival time of 11.7 ± 2.5 years compared with 24.3 ± 1.6 years for patients with the AA and AG genotypes. This evidence concerns the gene NFE2L2 and chronic myelogenous leukemia, BCR-ABL1 positive.